Abstract
With the rise of molecular profiling, detection of minimal residual disease (MRD) has emerged as a tool for risk stratification in patients with early stage CRC with potential implications for adjuvant therapy. We sought to evaluate the clinical course of predominantly early-stage colorectal cancer (CRC) patients who underwent MRD assessment using the Signatera™ ctDNA assay and the impact this approach had on clinical decisions at West Cancer Center and Research Institute (WCCRI).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
